Skip to main content

Table 1 COVID-19 patients’ clinical presentation and relevant laboratory findings (N = 1337) [28, 31]

From: Clinical progression of patients with COVID-19 in Lagos State, Nigeria

Symptoms or indications that are clinically significant  
Age, years
 Median (interquartile range) 50(35–63)
Sex 800(59.83%)
 Male (N, %)
 Female (N, %) 537(40.16%)
Days from one set of symptoms (days) 4(2–7)
Admission signs and symptoms (N, %)
 Fever 217(16.2%)
 Cough 211(15.78%)
 Fatigue 36(2.69%)
 Headache and dizziness 25(1.86%)
 Breathing problems 15(1.12%)
 Rhinorrhoea 19(1.42%)
 Sore throat 18(1.34%)
 Diarrhea 10(0.74%)
 Lack of appetence 11(0.82%)
 Asymptomatic 9(0.67%)
 Comorbidity (N, %) 100(7.47%)
 Cardiovascular and cerebrovascular diseases 66(4.93%)
 Endocrine system diseases 35(2.61%)
 Digestive system diseases 11(0.82%)
 Respiratory system diseases 8(0.59%)
 Chronic hepatitis B virus infection 4(0.29%)
 Malignant tumor 3(0.22%)
Laboratory findings
 White blood cells (× 10 9 per L) 4.71(3.80–5.86)
 Lymphocytes (× 10 9 per L) 1.12(0.79–1.49)
 C-reactive protein (mg/L) 12(4.4–29.4)
 Erythrocyte sedimentation rate (mm/h) 54(33–90)
 Alanine aminotransferase (U/L) 23(15–33)
 Aspartate aminotransferase (U/L) 25(20–33)
 Albumin (g/L) 40.8(37.9–43.0)
 Lactate dehydrogenase (U/L) 229(195–291)
 Lactate (mmol/L) 1.4(1.1–2.1)
 Estimated glomerular filtration rate (mL/min/1.73 m2) 109.2(95.3–127.2)
 CD4 T cells counts (cells/uL) 431(299–637)
 CD4/CD8 ratio 1.68(1.241.33)